195P Health-related quality of life outcomes in SOLTI VALENTINE: A trial of neoadjuvant HER3-DXd +/- letrozole for high-risk hormone receptor positive/HER2-negative early breast cancerGuillermo Villacampa, Ana Muntañola Prat, J. Cruz Jurado et al.|ESMO Open|2025Cited by 1
357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)S. Nucera, Daniele Generali, F. Schettini et al.|Annals of Oncology|2024Cited by 0
36P PROUDER-BC: PROsigna in UnDer-50-year-old patients (pts) with endocrine receptor-positive (ER+) breast cancer (BC) for chemotherapy (CT) prescriptionFrancesco Schettini, G Grazia, Vincenzo Di Lauro et al.|ESMO Open|2025Cited by 0
651eTiP CAPItana: A phase IIIb study to evaluate the use of capivasertib in combination with fulvestrant in patients with advanced breast cancer who have relapsed/progressed on endocrine therapy and CDK4/6 inhibitors reflecting real-world clinical practice in Spain NCT06764186Rodrigo Sánchez-Bayona, C. Saura Manich, Manuel Oliveira et al.|Annals of Oncology|2025Cited by 0